Category: EIC Transition

Introduction: Glioblastoma (GBM) remains the most aggressive brain tumour, with ~35,000 new cases annually across the US and Europe, a median overall survival of ~15 months, and a five-year survival of ~5%—highlighting the urgency for new treatment options. Beactica Therapeutics AB (Sweden), together with leading glioblastoma researchers at KU Leuven (Belgium), launched GLIOBREAK to advance …